Erica Farrand, MD

HS Asst Clinical Professor

Dr. Farrand is an Assistant Professor in the Division of Pulmonary, Critical Care, Sleep, Allergy and Sleep Medicine. She is attending physician in the Interstitial Lung Disease Program and on the Pulmonary Consult Service.

Dr. Farrand's scholarship focuses on defining, assessing and improving the health care quality, safety and outcomes for individuals with interstitial lung disease. She collaborates closely with colleagues in ILD, health services research, implementation science and informatics to support a multidisciplinary research program.

Education
2020 - Diversity, Equity, and Inclusion Champion Training, University of California, San Francisco
Pulmonary and Critical Care, 2019 - , University of California, San Francisco
2019 - Advanced Training in Clinical Research Certificate, University of California, San Francisco
Internal Medicine, 2013 - , NYP-Columbia University
School of Medicine, 2010 - , Columbia University
Publications

  1. Suen AO, Bischoff K, Iyer AS, Radhakrishnan K, Fenton C, Singer JP, Sudore RL, Kotwal A, Farrand E. Differences in Healthcare and Palliative Care Utilization at the End of Life: a Comparison Study Between Lung Cancer, COPD, and IPF. Chest 2024. PMID: 39186972


  2. Upadhyay V, Yoon YM, Vazquez SE, Velez TE, Jones KD, Lee CT, Law CS, Wolters PJ, Lee S, Yang MM, Farrand E, Noth I, Strek ME, Anderson MS, DeRisi JL, Sperling AI, Shum AK. Phage Immunoprecipitation-Sequencing Reveals CDHR5 Autoantibodies in Select Patients With Interstitial Lung Disease. ACR Open Rheumatology 2024. PMID: 38952015


  3. Koshy K, Barnes H, Farrand E, Glaspole I. Steroid therapy in acute exacerbation of fibrotic interstitial lung disease. Respirology (Carlton, Vic.) 2024. PMID: 38825348


  4. Mullin ML, Fernandez G, Marinescu DC, Zheng B, Wong AW, Assayag D, Fisher JH, Johannson KA, Khalil N, Kolb M, Manganas H, Marcoux V, Morisset J, Min B, Farrand E, Ryerson CJ. Impact of Antigen Exposure on Outcomes and Treatment Response in Fibrotic Hypersensitivity Pneumonitis. Chest 2023. PMID: 38128609


  5. Suen AO, Iyer AS, Cenzer I, Farrand E, White DB, Singer J, Sudore R, Kotwal A. National Prevalence of Social Isolation and Loneliness in Adults with Chronic Obstructive Pulmonary Disease. Annals of the American Thoracic Society 2023. PMID: 37463307


  6. Farrand E, Swigris JJ. Digital outcome measures in pulmonary clinical trials. Current opinion in pulmonary medicine 2023. PMID: 37191175


  7. Farrand E, Gologorskaya O, Mills H, Radhakrishnan L, Collard HR, Butte AJ. Machine Learning Algorithm to Improve Cohort Identification in Interstitial Lung Disease. American journal of respiratory and critical care medicine 2023. PMID: 36943196


  8. Farrand E, Collard HR, Guarnieri M, Minowada G, Block L, Lee M, Iribarren C. Extracting patient-level data from the electronic health record: Expanding opportunities for health system research. PloS one 2023. PMID: 36897886


  9. Kerkhoff AD, Farrand E, Marquez C, Cattamanchi A, Handley MA. Addressing health disparities through implementation science-a need to integrate an equity lens from the outset. 2022. PMID: 35101088


  10. Comes A, Wong AW, Fisher JH, Morisset J, Johannson KA, Farrand E, Fell CD, Kolb M, Manganas H, Cox G, Gershon AS, Halayko AJ, Hambly N, Khalil N, Sadatsafavi M, Shapera S, To T, Wilcox PG, Collard HR, Ryerson CJ. Association of Body Mass Index and Change in Weight with Mortality in Patients with Fibrotic Interstitial Lung Disease. 2021. PMID: 34788669


  11. DeDent AM, Farrand E. Vaccine-induced interstitial lung disease: a rare reaction to COVID-19 vaccination. Thorax 2021. PMID: 34510014


  12. Farrand E, Limper AH. Clinical Trials for Idiopathic Pulmonary Fibrosis and the Role of Health Systems. Clinics in chest medicine 2021. PMID: 34024404


  13. Santhosh L, Harleman E, Venado A, Farrand E, E Gilbreth M, Keenan BP, Thompson VV, Shah RJ. Strategies for forming effective women's groups. The clinical teacher 2020. PMID: 33058547


  14. Farrand E, Iribarren C, Vittinghoff E, Levine-Hall T, Ley B, Minowada G, Collard HR. Impact of idiopathic pulmonary fibrosis on longitudinal healthcare utilization in a community-based cohort of patients. Chest 2020. PMID: 32717266


  15. Farrand E, Collard HR. Is corticosteroid use truly not associated with improved outcomes in AE-IPF? - Reply. Respirology (Carlton, Vic.) 2020. PMID: 32307799


  16. Farrand E, Vittinghoff E, Ley B, Butte AJ, Collard HR. Corticosteroid use is not associated with improved outcomes in acute exacerbation of IPF. Respirology (Carlton, Vic.) 2019. PMID: 31846126


  17. Farrand E, Anstrom KJ, Bernard G, Butte AJ, Iribarren C, Ley B, Martinez F, Collard HR. Closing the Evidence Gap in Interstitial Lung Disease: The Promise of Real World Data. American journal of respiratory and critical care medicine 2018. PMID: 30452876


  18. Farrand E, Shah R, Collard H. The Hospitalized Patient with Interstitial Lung Disease: A Hospitalist Primer. Journal of hospital medicine 2017. PMID: 28699950


  19. Verna EC, Brown RS, Farrand E, Pichardo EM, Forster CS, Sola-Del Valle DA, Adkins SH, Sise ME, Oliver JA, Radhakrishnan J, Barasch JM, Nickolas TL. Urinary neutrophil gelatinase-associated lipocalin predicts mortality and identifies acute kidney injury in cirrhosis. Digestive diseases and sciences 2012. PMID: 22562534


  20. Verna EC, Valadao R, Farrand E, Pichardo EM, Lai JC, Terrault NA, Brown RS. Effects of ethnicity and socioeconomic status on survival and severity of fibrosis in liver transplant recipients with hepatitis C virus. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2012. PMID: 22467547


  21. Verna EC, Farrand ED, Elnaggar AS, Pichardo EM, Balducci A, Emond JC, Guarrera JV, Brown RS. Basiliximab induction and delayed calcineurin inhibitor initiation in liver transplant recipients with renal insufficiency. Transplantation 2011. PMID: 21617588